Macrocyclic inhibitors of hepatitis C virus

Details Macrocyclic inhibitors of hepatitis C virus Macrocyclic inhibitors of hepatitis C virus

2011-08-30

2011-08-30

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021100, C514S021910, C540S460000

Reexamination Certificate

active

08008251

ABSTRACT:
Inhibitors of HCV of formula (I).and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1is hydrogen or C1-6alkyl; R2is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6;pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

REFERENCES:
patent: 5484801 (1996-01-01), Al-Razzak
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5948436 (1999-09-01), Venkat
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6344465 (2002-02-01), Armistead et al.
patent: 6498178 (2002-12-01), Stamos et al.
patent: 6867185 (2005-03-01), Campbell et al.
patent: WO 94/14436 (1994-07-01), None
patent: WO 95/07696 (1995-03-01), None
patent: WO 95/09614 (1995-04-01), None
patent: WO 97/40028 (1997-10-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/40381 (1998-09-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/56331 (2000-09-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 2005/073195 (2005-08-01), None
patent: WO 2005/073216 (2005-08-01), None
Bodanszky, M., “Peptide Chemistry”, 2ndRed. Ed., Springer-Verlag, Berlin, Germany (1993). Title Page and Table of Contents.
Goodman and Gillman's “The Pharmacological Basis of Therapeutics” Eighth Edition, McGraw-Hill, Inc., Health Professions Division, p. 1-20 (Title Page and Table of Contents), (1991).
Greene, “Protective Groups in Organic Chemistry”, Wiley & Sons, NY (1999) “The Peptides: Analysis, Synthesis, Biology”, vol. 9, Academic Press, NY (1987) (Title Page and Table of Contents).
Huang, et al., “Olefin Metathesis-Active Ruthenium Complexes Bearing a Nucleophilic Carbene Ligand” J. Am. Chem. Soc. 1999 121, p. 2674-2678.
Kingsbury, J., “A Recyclable Ru-Based Metathesis Catalyst”, et al., J. Am. Chem. Soc. 1999, 121, p. 791-799.
Krchnak, V. et al., “Polymer-Supported Mitsunobu Ether Formation and its Use in Combinatorial Chemistry”, Tetrahedron Letters, vol. 36, No. 35, p. 6193-6195, 1995.
Krieger, N., et al., “Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations”, Journal of Virology, May 2001, pp. 4614-4624.
Liu, Y., et al. “Use of a Fluorescence Plate Reader for Measuring Kinetic Parameters with Inner Filter Effect Correction”, Analytical Biochemistry 267, pp. 331-335 (1999).
Lohmann, V., et al., “Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line”, Science 285, 1999, pp. 110-113.
Miller, S., et al., “Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides”, J. Am. Chem. Soc. 1996, 118, p. 9606-9614.
Mitsunobu, O., “The Use of Diethyl Azodicraboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products”, Synthesis, Jan. 1-28, 1981.
Rano, T. et al., “Solid Phase Synthesis of Aryl Ethers via the Mitsunobu Reaction”, Tetrahedron Letters, vol. 36, No. 22, pp. 3789-3792, 1995.
Richter, L. et al, “A Surprising Observation about Mitsunobu Reactions in Solid Phase Synthesis”, Tetrahedron Letters, vol. 35, No. 27, p. 4705-4706, 1994.
Hou, Tingjun et al. “pharmacophore Model and 3D-QSAR study of two kinds of HCV NS3 Serine protease Inhibitiors”, Acta Physico-Chimica Sinica, vol. 16, No. 3, pp. 196-201 (2000).
Landro, “Mechanistic Role of an NS4A Peptide Cofactor with the Truncated NS3 Protease of Hepatitis C Virus: Elucidation of the NS4A Stimulatory Effect via Kinetic Analysis and Inhibitor Mapping”, Biochemistry, vol. 36, pp. 9340-9348 (1997).
Poliakov, “Expression and Purification of Recombinant Full-Length NS3 Protease-Helicase from a New Variant of Hepatitis C Virus”, Protein Expression and Purification, vol. 25, pp. 363-371 (2002).
Smith, E.M., et al. “Synthesis and Pharmacological Activity of Angiotensin Converting Enzyme Inhibitors: N-(Mercaptoacyl)-4-substituted-(S)-prolines” Journal of Medicinal Chemistry, vol. 31, pp. 875-885 (1988).

Affiliated with

Also associated with

Rating

Macrocyclic inhibitors of hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic inhibitors of hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic inhibitors of hepatitis C virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2710092